Your Heart. Our Priority.


CardioDiagnostics is a medical technology company specialized in cardiac care solutions. Established in USA with global R&D offices, the company develops proprietary technologies for wireless monitoring of cardiac patients. Our team of ambitious entrepreneurs, technologists, medical experts and industry veterans are working together to meet the market needs and solve existing problems in the cardiac care industry through research-based pioneering technologies.


CardioDiagnostics is focused on helping physicians diagnose and treat patients with cardiac problems. Our team is dedicated to providing patients and their physicians with the best cardiac monitoring technologies in the world. Patient comfort and care is pivotal. Patients may continue normal day-to-day lifestyle, while CardioDiagnostics makes sure that physicians receive vital cardiac information needed to make a proper diagnosis.


At CardioDiagnostics, we envision a world where cardiac disease is no longer the leading cause of death. Our mission is to reinvent cardiac care through world-class pioneering technologies.

Our Solutions

Transforming Healthcare

Hospital and Clinical Services
Patient Monitoring

  • LifeSense Arrhythmia More
  • LifeSense Ischemia More

Software Services
Efficient Cardiac Care

  • Remote Monitoring Systems More
  • Analytical Algorithms More

LifeSense Arrhythmia

LifeSense Arrhythmia is an advanced wireless monitoring system using FDA-approved devices equipped with proprietary algorithms to automatically detect, record and transmit wirelessly a wide range of cardiac events, allowing physicians to monitor patients continuously, in real-time, up to 30 days.

Why LifeSense Arrhythmia?

Some arrhythmias occur too infrequently to be detected via the current monitoring technologies (Holters, Event monitors, etc). Patients with such arrhythmias require efficient and reliable long-term continuous real-time monitoring.

Types of Conditions Monitored
  • Tachycardia
  • Bradycardia
  • Asystole and Syncope
  • Atrial fibrillation
  • Pause
  • Others

Data Transmission

Occurs in two ways:

  • Automatic transmission when an abnormality is detected by the device, mostly for asymptomatic events.
  • Patient triggered for symptomatic events.

The ECG, location, and other vital information are transmitted to a dedicated monitoring center where professional medical experts evaluate events, and respond accordingly. Physicians have access to their real-time patient data from any internet-connected device.

Selected Device Features

  • Seamless Access to Results around the Clock
  • Removable Micro SD
  • Patient Alerts (for low battery, disconnected electrode, and message from Physician/Monitoring center)
  • Simple Device Interface
  • Continuous data recording for up to 30 days

LifeSense Ischemia

LifeSense Ischemia is an advanced solution that integrates 12-lead electrodes into fabric to detect specific physiological variations indicative of a potential ischemia. The system's intelligent algorithms continuously analyse data, searching for early signs of cardiac Ischemia, a condition that may lead to a heart attack.

Why LifeSense Ischemia?

Ischemia and other Coronary Artery Diseases (CAD) may develop into a heart attack. For patients with ischemia, time is very critical. Such patients develop ECG-visible symptoms of pathology, along other physiological changes. If these symptoms are detected early enough, patients will have a greater chance of survival and recovery.

Product is in R & D

"Content Under Construction, stay tuned for the latest news."

Software Services

Remote Monitoring Systems

CardioDiagnostics is specialized in developing advanced remote monitoring systems for various monitoring applications. For more information about our Remote Monitoring Systems, Contact Us now.


Analytical Algorithms

CardioDiagnotics develops proprietary analytical algorithms designed to identify patterns of abnormality with high sensitivity and specificity. Our algorithms enable physicians and caregivers to make accurate diagnoses of their patients quickly and cost effectively.


Because We Care

Patient Care
Dedication and Comfort

At CardioDiagnostics, we're dedicated to providing you with the best cardiac monitoring products and services. You may continue with your lifestyle normally, while your physician receives the vital information needed to make the proper diagnosis.
Our Patient Care personnel will work with you to setup your monitoring equipment and initiate monitoring. They are available 24/7 to answer any questions you have during the monitoring period. CardioDiagnostics' Patient Care Team is trained to proactively manage each patient timely, ensuring all questions are answered and any issues are resolved promptly.


Patient Experience
Your Experience Matters

We believe that sharing your experience with CardioDiagnostics will help us excel at providing the best care and comfort to our patients. Please do not hesitate to share your story with us, and join thousands whose lives have been changed using CardioDiagnostics products and services.

Patient Privacy
Physician-Patient Confidentiality

At CardioDiagnostics, we appreciate the notion of patient privacy. Our systems integrate the highest HIPAA standards of privacy and security.


Financial Information
CardioDiagnostics targets institutional investors who believe in the company's technology, team, and vision. CardioDiagnostics partners with select investors who bring their offerings beyond the dollar value. If you are interested in knowing more about our latest technologies and investment opportunities, please feel free to Contact Us.
Market Size
The global cardiac monitoring market is expected to grow to $23.3 Billion in 2017 (Markets and Markets, 2014). In 2010, it is estimated that around 2.2 million patients used remote monitoring in the U.S. alone. This number is expected to reach 6 millions in 2016 (Markets and Markets, 2014). These figures clearly show the market opportunity for the cutting-edge monitoring technologies developed by CardioDiagnostics. We are Raising Funds. If you wish to be part of the game, do not hesitate to Contact Us. Check out the latest Articles on the benefits and the growing need for Wireless Cardiac Monitoring Solutions.
CardioDiagnostics Technologies
CardioDiagnostics developed the World's First HIPAA-Compliant, Secure, Cloud-Based Cardiac Management System accessible from any internet connected device. CardioDiagnostics continues to develop proprietary technologies addressed at the larger audience to help prevent cardiac conditions.

News and Articles

Benefits of Monitoring Patients with Mobile Cardiac Telemetry (MCT)

This research is meant to establish if a patient monitored with mobile cardiac telemetry (MCT) sees different outcomes regarding diagnostic yield of arrhythmia, therapeutic management through the use of antiarrhythmic drugs, and cardiovascular costs incurred in the hospital setting when compared with more traditional monitoring devices, such as the Holter or the Event monitor.
Study: A retrospective analysis was conducted spanning 57 months of claims data from January 2007 to September 2011 pertaining to 200,000+ patients, of whom 14,000 used MCT only, 54,000 an Event monitor only, and 163,000 a Holter monitor only.
Conclusion: First, the diagnostic yield of patients monitored with MCT is 61%, that is significantly higher than that of patients that use the Event monitor (23%) or the Holter monitor (24%). Second, patients naive to antiarrhythmic drugs initiate drug therapy after monitoring at the following rates: 61% for patients that use MCT compared with 39% for patients that use the Event and 43% for patients that use the Holter. Third, there are very significant inpatient cardiovascular savings (in the tens of thousands of dollars) for patients that undergo ablation, coronary artery bypass graft (CABG) and valve septa. Savings are more modest but nonetheless significant when it comes to the heart/pericardium procedure. Given the superior outcome of MCT regarding both patient care and hospital savings, hospitals only stand to gain by enforcing protocols that favor the MCT system over the Event or the Holter monitor.

The Value of Mobile Cardiac Telemetry

In the article "Contemporary Reviews in Cardiovascular Medicine" by M.D. Peter Zimetbaum and Alena Goldman, a study was conducted to compare real- time telemetry with 24-hour Holters.
Study: One of the studies that were conducted involves one randomized controlled trial involving 266 patients with a high clinical suspicion for a malignant arrhythmia, history of syncope, presyncope, or severe infrequent palpitations and a no-diagnostic 24-hour Holter.
Conclusion: 41.4% of patients in the real-time telemetry group had detection of a clinically significant arrhythmia. Another two Prospective studies were done using MCOT and resulted with a diagnostic yield of 88% and 50%.


Atrial fibrillation is a leading cause of recurrent stroke. Early detection, diagnosis and treatment are critical.
Study: A study was conducted that involves patients without known atrial fibrillation who had a cryptogenic ischemic stroke within the previous 6 months. The patients undergo additional noninvasive ambulatory ECG monitoring with either a 30-day event-triggered recorder (intervention group) or a conventional 24-hour monitor (control group).
Conclusion: Noninvasive ambulatory ECG monitoring for a target of 30 days significantly improved the detection of atrial fibrillation by a factor of more than five and nearly doubled the rate of anticoagulant treatment, as compared with the standard practice of short-duration ECG monitoring.

Telemonitoring Reduces Readmissions 44 Percent in 4-Year, 500 Patient Study

According to research conducted by the American Heart Association, roughly 5.1 million Americans have heart failure. Approximately half of the patients who experience the disease die within five years of diagnosis.
Study: A study conducted by Pennsylvania hospital system Geisinger Health Plan aimed at quantifying the benefit and value of remote patient monitoring in diagnosing patients with heart failure. The research was restricted to 541 patients. These patients remained on the plan for a full 70-month study (which included a year of data prior to the start of the intervention). The study had no control groups; instead each member's claims data for months they were enrolled in the intervention was compared to claims data when they were not.
Conclusion: Study shows that the remote monitoring program reduces 30-day readmissions by 44 percent and 90-day readmissions by 38 percent. Overall costs are reduced by 11 percent.

Powered by Talent, Driven by Innovation

We highly Invest in our talents and believe that every single member of our family makes a big contribution towards our success.

To apply, kindly send your CV to: info@cardiodiagnostics.net

Software Innovation Engineers

Majors: CCE, Computer Science, IT, other relevant majors
Years Of Experience: (0-8) years
Number of Positions: Multiple

Chief of Strategy and Operations

Majors: Engineering background, MBA from EU or USA
Years Of Experience: (3-8) years
Number of Positions: 1

Community Manager and Executive Assistant

Majors: Business background
Years Of Experience: (0-8) years
Number of Positions: 1

Business Development Manager

Majors: Engineering, business background
Years Of Experience: (0-8) years
Number of Positions: 1 (San Francisco Office)

Get In Touch With Us

Where you can find us

1521 Concord Pike
Suite 301, Wilmington DE 19803

Our mail and phone

E: info@cardiodiagnostics.net
P: 415-670-9232

When you can find us

M-Sa: 9 AM - 6 PM
Su: Closed